

# TABLE OF CONTENTS

November 2, 2009

No. 2162

## BUSINESS

- 1 Roche to Strengthen Partnering in Japan: Mr McCracken
  - T-DM1 Is a Key Product in Oncology
- 2 Pfizer Completes Acquisition of Wyeth
- 2 DSP Completes Acquisition of Sepracor Inc.
- 2 Teijin Sublicenses TMX-67 to Menarini in Europe
- 3 Eisai Licenses Denileukin Diftitox to TSD Japan
- 3 Top-Five Wholesalers Revise Half-Year Business Forecasts Upward
- 3 **TOPICS**
  - Mr Hasegawa Appointed Chairman of MLIT's Growth Strategy Council
- 4 Medipal Ties Up with China's Largest Drug Wholesaler
- 4 **BUSINESS NEWS IN BRIEF**
  - Kyowa Kirin Transfers Neu-Up to Yakult
  - BioWa Licenses POTELLIGENT Technology to NKTT
  - Sanofi-aventis Licenses New Anti-Diabetic Agent from Wellstat Pharmaceuticals
  - EP-Mint to Acquire Sogo SMO: EPS

## GENERICS

- 5 Generics Use Rate by Far the Highest in Okinawa Prefecture

## REGULATORY

- 6 35 Products Approved Including Januvia/Glactiv
  - Japan's 1st DPP-4 Inhibitor Januvia/Glactiv Approved: Banyu, Ono
  - Prevenar Approved as Japan's 1st Pneumococcal Vaccine: Wyeth
  - HPV Vaccine Cervarix Approved: GSK
  - Rasuritek Approved for Chemotherapy-Associated Hyperuricemia: sanofi-aventis
  - Erizas Approved for Allergic Rhinitis: Nippon Shinyaku
  - Emend Capsule Approved for CINV: Ono
  - Miripla Approved for Hepatocellular Carcinoma: DSP
  - Symbicort Turbuhaler Approved for Bronchial Asthma: AZ
  - Asacol Approved for Ulcerative Colitis: Zeria
  - Ozex Fine Granules for Children Approved: Toyama Chemical
  - Factor IX Preparation BeneFix Approved: Wyeth
  - Adcirca Approved for PAH: Eli Lilly Japan
  - Basen Approved to Prevent Type 2 Diabetes in Patients with IGT: Takeda
  - Paxil Approved for SAD as Add'l Indication: GSK
  - Feron Approved for Chronic Hepatitis C in Combination with Ribavirin: Toray
  - Prograf Approved for All Types of Myasthenia Gravis
- 10 Bridion Recommended for Approval
  - BI-Sifrol Recommended for Approval for RLS
  - Bridion Recommended for Approval in Japan while FDA Hangs Back

- 11 *Koroshō* Increases FY2010 Budget Request to ¥28,889.4 Bil.
- 12 Hatoyama Administration to Change Medical Expenditure Curtailment Policy
- 13 Lawmakers to Have Stronger Influence on Medical Fees
- 13 3 JMA Top Management Team Members Not Re-appointed as *Chuikyo* Members
- 14 Price Maintenance System Essential to Make Drug Market in Japan More Attractive: Mr Kinoshita
  - Price Maintenance System Will Stimulate Industry: Mr Naito
- 14 *Koroshō* to Issue Guidance for Transmission of Safety Information
- 15 **REGULATORY NEWS IN BRIEF**
  - Fentanyl Transdermal System Approved for Chronic Pain in the US: Hisamitsu
  - Chugai's Avastin Applied for Breast Cancer
  - Eldecalcitol Applied for Osteoporosis: Chugai, Taisho
  - Industry Leaders Pay First Courtesy Call to *Koroshō*
  - *Koroshō* Reorganization May Become a Hot Topic Again

## COMMENTARY

- 16 Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics: Keiji Nakamura, Ph. D.

## R&D

- 20 Kyowa Kirin to Apply for KW-0761 Hopefully in 2011
- 20 Astellas, IBL Discontinue Development of ASK8007 as Anti-RA Drug
- 20 Eliminate "Drug Lag" at Initiative of Politicians: Mr Sekiguchi
- 21 Global Trials Conducted by EFPIA Member Companies Show Sharp Increase
- 22 **R&D NEWS IN BRIEF**
  - Ono Ties Up with Evotec for Ion Channel Drug Discovery
  - BSP Ties Up with AC Immune in AD Vaccine Development Program
  - NanoCarrier's NC-4016 to Be Patented in Europe

## MEDICAL FACILITIES & NURSING CARE

- 22 *Koroshō* to Increase Financial Assistance for IFN Therapy
- 23 **Topics**
  - JMA to Reconsider Its Relationship with LDP
  - President of Ibaraki Medical Association to Run for JMA Presidency

## MEDICAL DEVICES

- 23 Terumo's Drug-Saving FN Syringe Approved in 3 Months